Effect of ON101 Topical Cream on Infected Diabetic Foot Ulcer: A Case Series in the US Elderly Patients.

Methods

  • Design: Prospective case series (n=4)
  • Site: Wound Clinic at Casa Colina Hospital
  • Inclusion Criteria:
    • Age > 60,  Wagner Grade 2DFU with mild infection (IDSA Grade 2)
    • Concurrent systemic antibiotics
  • Exclusion Criteria: Dialysis or inadequate perfusion
  • Treatment Protocol:
    • ON101 applied twice daily for up to 8 weeks
    • Weekly clinic assessment and image documentation
  • Perfusion Assessment: ABI / TBI / Pedal pulse
  • Outcome Measures:
    • Wound area reduction
    • Healing time
    • Safety (adverse events)

 

Executive Summary

This case series highlights ON101’s potential as an effective adjunctive treatment for iDFUs in elderly, PAD-complicated patients. Despite advanced age (mean 72.3 yrs), amputation history (3/4), and long-standing diabetes (>10 years), ON101 facilitated:

  • Fast wound closure (6-9 weeks)
  • Marked wound size reduction
  • No adverse effects
  • High patient compliance in real-world US clinical setting
  • Subjects reported decreased pain sensation

These findings suggest ON101 can enhance limb preservation and quality of life even in high-risk elderly wound populations.

 

Conclusion

ON101 was safe, well-tolerated, and clinically effective in elderly patients with infected DFUs, promoting healing even in complex cases with amputation history and PAD.

 

Conference PublicationSAWC Fall 2025
Date PublishedSeptember 3rd, 2024
Authors InformationChia-Ding Shih, DPM, MPH; Erianthe Ortega, BSN; Emily R. Rosario, PhD
Poster Presentation

Effect of ON101 Topical Cream on Infected Diabetic Foot Ulcer: A Case Series in the US Elderly Patients.

Introduction

Diabetic foot ulcers (DFUs) in the elderly present significant challenges due to comorbidities like peripheral arterial disease (PAD), long-standing diabetes, and infection. While ON101 has demonstrated promise in general DFU management, its application in infected DFUs (iDFUs) in elderly populations remains underreported. This prospective case series investigates ON101’s real-world performance in US elderly patients with Wagner grade 2 iDFUs.